Contrasting Conduit Pharmaceuticals (CDT) and The Competition

Conduit Pharmaceuticals (NASDAQ:CDT) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Conduit Pharmaceuticals to related businesses based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, profitability, dividends and risk.

Analyst Ratings

This is a summary of recent ratings and target prices for Conduit Pharmaceuticals and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conduit Pharmaceuticals	0	0	0	1	4.00
Conduit Pharmaceuticals Competitors	8418	22263	50414	1350	2.54

As a group, “Pharmaceutical preparations” companies have a potential upside of 252.91%. Given Conduit Pharmaceuticals’ rivals higher probable upside, analysts clearly believe Conduit Pharmaceuticals has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Conduit Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Conduit Pharmaceuticals	N/A	-$540,000.00	-0.02
Conduit Pharmaceuticals Competitors	$9.89 billion	$136.37 million	-5.46

Conduit Pharmaceuticals’ rivals have higher revenue and earnings than Conduit Pharmaceuticals. Conduit Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Conduit Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Conduit Pharmaceuticals	N/A	N/A	-328.67%
Conduit Pharmaceuticals Competitors	-3,399.87%	-235.11%	-32.77%

Institutional & Insider Ownership

3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 30.9% of Conduit Pharmaceuticals shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Conduit Pharmaceuticals has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals’ rivals have a beta of 3.87, indicating that their average stock price is 287% more volatile than the S&P 500.

Summary

Conduit Pharmaceuticals rivals beat Conduit Pharmaceuticals on 7 of the 13 factors compared.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.